Sep 13, 2016 | Uncategorized
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR...
Sep 13, 2016 | Uncategorized
The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (Tagrisso) is effective in the first-line treatment of EGFR-mutated non–small cell lung cancer (NSCLC), according to a late-breaking abstract presented by Ramalingam...
Sep 13, 2016 | Uncategorized
AstraZeneca today announced that the European Commission (EC) has granted conditional marketing authorisation for TAGRISSO™ (AZD9291, osimertinib) 80mg once-daily tablets for the treatment of adult patients with locally advanced or metastatic epidermal growth factor...
Sep 13, 2016 | Uncategorized
Lung and other thoracic tumours/ Anticancer agents & Biologic therapy GENEVA, Switzerland – The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated...
